wilms tumor/nausea

Veza se sprema u međuspremnik

Odaberite vrstu sortiranja

14 rezultatima

Wilms' Tumor With Intra-Atrial Extension: Treatment and Management.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Wilms' tumor is the most common renal cancer in children. It can grow for a long time without any characteristic symptoms, causing only fever, abdominal pain, nausea, or vomiting, which is the reason why it is often discovered accidentally. In 1% to 4% of the cases, nephroblastoma leads to

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Background: Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate linking an antimitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). Preclinical efficacy has been noted in Wilms tumor, rhabdomyosarcoma, and

Combination chemotherapy with adramycin (NSC-123127) and dimethyl triazeno imidazole carboxamide (DTIC) (NSC-45388) in children with metastatic solid tumors.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Combination chemotherapy with adriamycin and DTIC was used in 102 evaluable patients under 15 years of age who had previously treated metastatic solid tumors. Responses, defined as 50% or more reduction in all tumor masses, occurred in 10 out of 27 patients with neuroblastoma, 3 out of 8 patients

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVE To determine the toxicity profile, dose-limiting toxicities, and maximum tolerated dose of ABT-751 administered orally once daily for 7 days, repeated every 21 days. METHODS Patients who were

A massive retroperitoneal neuroblastoma with stenosis of the inferior vena cava in a 5-month-old boy.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Neuroblastoma is the second most common retroperitoneal tumour in children after Wilms' tumour. When it originates in the retroperitoneum, neuroblastoma usually presents as an abdominal mass with clinical manifestations of nausea, vomiting and weight loss. Imaging studies of this tumour demonstrate

Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Ninety-eight children with solid tumors resistant to conventional chemotherapy received adriamycin 90 mg/m2, either as a single intravenous injection or in 6 divided doses administered every 6 hours. Of the 88 evaluable children, 6 (7%) achieved a complete response and 26 (29%) achieved a partial

Phase II trial of ifosfamide in children with malignant solid tumors.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Ifosfamide was given to 61 patients with malignant solid tumors diagnosed before the age of 21 years. In this phase II study, all patients received 1.6 g/m2/day X 5 iv over 15 minutes followed by mesna at a dose of 400 mg/m2 iv at 15 minutes and 4 and 6 hours after ifosfamide. Responses were

Ifosfamide in pediatric malignant solid tumors.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Ifosfamide/mesna was given to 97 patients who had malignant solid tumors diagnosed before they were 21 years of age. Patients received 1.6 g/m2 ifosfamide daily x 5, given i.v. over 15 min, followed by 400 mg/m2 i.v. mesna at 15 min and 4 and 6 h after ifosfamide. Responses were noted in patients

Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVE To determine the maximum-tolerated dose (MTD) of all-trans-retinoic acid (ATRA) administered on an intermittent oral schedule with interferon-alpha2a (IFN-alpha2a) in children with refractory cancer, and whether the marked reduction in plasma ATRA concentrations observed with chronic daily

Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

BACKGROUND To determine the MTD of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors. Patients (≥ 3-≤ 21 years) with neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features were eligible. METHODS Part A (single dose of NTX-010) enrolled 13 patients

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

OBJECTIVE Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. METHODS Gefitinib (150, 300, 400, or 500 mg/m2) was

5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of solid tumors in children.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) was administered to 46 children with various solid tumors which were resistant to conventional therapy. Two or more courses of NSC-45388 were administered to 13 of 18 children with neuroblastoma, seven of 11 children with

Chemotherapy combined with apatinib for the treatment of desmoplastic small round cell tumors: A case report

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Desmoplastic small round cell tumor (DSRCT) is a type of soft-tissue sarcoma with poor prognosis. Current treatments include multidisciplinary treatment options such as surgery, chemotherapy, and radiotherapy. Apatinib is an oral, small-molecule, anti-tumor, angiogenesis-targeted drug, which acts

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

BACKGROUND We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors. METHODS Patients received cabozantinib tablets on a

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta znanošću

Radi na 55 jezika
Biljni lijekovi potpomognuti znanošću
Prepoznavanje bilja slikom
Interaktivna GPS karta - označite bilje na mjestu (uskoro)
Pročitajte znanstvene publikacije povezane s vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima